{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:59:29Z","timestamp":1792673969788,"version":"4.5.0"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Stable, homotypic mutants of\n            <jats:italic>Chlamydia trachomatis<\/jats:italic>\n            for which MICs of rifampin and rifalazil are elevated were isolated by serial passage at sub-MIC concentrations of these compounds. An alternative approach, in which\n            <jats:italic>Chlamydia<\/jats:italic>\n            cells were incubated and subsequently passaged three times, all in the presence of the selective agent at concentrations above the MIC, appeared to be a more effective means of selecting for mutants. In every instance where an elevation in the MIC occurred, one or more mutations in the\n            <jats:italic>rpoB<\/jats:italic>\n            gene, encoding the rifampin binding site, were detected. With one exception, all\n            <jats:italic>rpoB<\/jats:italic>\n            mutants that contained a single mutation conferred lower levels of resistance than mutants containing multiple mutations. Some\n            <jats:italic>rpoB<\/jats:italic>\n            mutations conferred very high levels of resistance to rifampin, up to 512 \u03bcg\/ml. In all cases, mutants remained susceptible to concentrations of rifalazil at or below 0.064 \u03bcg\/ml. Thus, rifalazil, a compound that is extremely potent against\n            <jats:italic>Chlamydia<\/jats:italic>\n            wild-type cells (MIC of 0.00025 \u03bcg\/ml), may also protect against the selection of mutants at physiologically achievable concentrations.\n          <\/jats:p>","DOI":"10.1128\/aac.49.3.1120-1126.2005","type":"journal-article","created":{"date-parts":[[2005,2,23]],"date-time":"2005-02-23T22:51:53Z","timestamp":1109199113000},"page":"1120-1126","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":35,"title":["Rifampin-Resistant RNA Polymerase Mutants of\n            <i>Chlamydia trachomatis<\/i>\n            Remain Susceptible to the Ansamycin Rifalazil"],"prefix":"10.1128","volume":"49","author":[{"given":"Robert J.","family":"Suchland","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne\u0300s","family":"Bourillon","sequence":"additional","affiliation":[{"name":"INSERM E0339, Faculte\u0301 de Me\u0301decine Xavier Bichat, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Denamur","sequence":"additional","affiliation":[{"name":"INSERM E0339, Faculte\u0301 de Me\u0301decine Xavier Bichat, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E.","family":"Stamm","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Rothstein","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00286-0"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/315778"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.1972-1976.2001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2316-2318.2003"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.1118"},{"key":"e_1_3_2_7_2","unstructured":"Infectious disease and therapy series vol. 21. 1997"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2655"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.2.532-539.2001"},{"key":"e_1_3_2_11_2","first-page":"166","volume":"6","year":"2002","unstructured":"Park, Y. K., B. J. Kim, S. Ryu, Y. H. Kook, Y. K. Choe, G. H. Bai, and S. J. Kim. 2002. Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis.6:166-170.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1135-1136.2003"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.2.255"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"S562","DOI":"10.1093\/clinids\/5.Supplement_3.S562","volume":"5","year":"1983","unstructured":"Schachter, J. 1983. Rifampin in chlamydial infections. Rev. Infect. Dis.5(Suppl. 3):S562-S564.","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_2_15_2","unstructured":"Stamm W. E. W. M. Geisler and R. J. Suchland. 2002. Assessment of antimicrobial resistance in Chlamydia trachomatis strains associated with treatment failure or same strain recurrence p. 353-360. In Chlamydial infections: Proceedings of the 10th International Symposium on Human Chlamydial Infections. Basim Yeri: GRAFMAT Basim ve Reklam Sanayi Tic. Ltd. Sti. Antalya Turkey."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.636-642.2003"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2813"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.2.153"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1853"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.5.621"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.3.1120-1126.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.3.1120-1126.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:46:33Z","timestamp":1645469193000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.3.1120-1126.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1128\/AAC.49.3.1120-1126.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.3.1120-1126.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"2004-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-11-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}